TORONTO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced results of a post-hoc analysis of data collected during the ARIES-1, ARIES-2 and ARIES-E studies for Letairis® in pulmonary arterial hypertension (PAH) (WHO Group 1) patients with primarily WHO functional class II or III symptoms. This analysis compared one-year clinical outcomes for PAH (WHO Group 1) patients who initially received placebo during the 12-week, placebo-controlled ARIES-1 and ARIES-2 studies before receiving ambrisentan during a long-term, open-label extension study (ARIES-E) to patients receiving continuous ambrisentan treatment throughout the ARIES studies. Data from this analysis were presented by Vallerie McLaughlin, MD, Associate Professor of Medicine, Director, Pulmonary Hypertension Program at the University of Michigan Health System, at ATS 2008 • Toronto, the International Conference of the American Thoracic Society, taking place May 16-21. Letairis (ambrisentan 5 mg and 10 mg tablets) is indicated as a once-daily treatment for PAH (WHO Group 1) in patients with WHO functional class II or III symptoms to improve exercise capacity and delay clinical worsening.
